Gilead Sciences Inc (NAS:GILD)
$ 65.96 1.38 (2.14%) Market Cap: 82.18 Bil Enterprise Value: 100.96 Bil PE Ratio: 183.22 PB Ratio: 4.69 GF Score: 77/100

Gilead Sciences Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 04, 2021 / 05:10PM GMT
Release Date Price: $63.23 (+0.76%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good afternoon, and welcome once again to Cowen and Company's 41st Annual Healthcare Conference. I'm Phil Nadeau, biotech analyst here at Cowen. It's my pleasure to introduce -- to moderate a fireside chat with Gilead Sciences. Happy to have with us today, Johanna Mercier, the Chief Commercial Officer; as well as Andy Dickinson, Chief Financial Officer.

First, maybe I'll turn it over to you guys. Could you just give a brief state of the company overview, biggest strengths, biggest challenges? And what needs to happen to continue to grow Gilead and create shareholder value over the next 12 to 24 months?

Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO

Sure. Hi, Phil. I'll start, and Johanna can jump in as well. Thanks for having us again at the conference. We appreciate it.

Look, I think it's -- we're really excited. 2021 is going to be an important year for Gilead. There's a real, palpable sense of excitement across the company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot